Business
Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results
Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results Cana...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VICTORIA, BC\n \n ,\n \n Nov. 10, 2021\n \n /CNW/ - Eupraxia Pharmaceuticals Inc.\n \n \n (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or \"IFRS\") and operational highlights for the third quarter ended\n \n September 30, 2021\n \n . All amounts are expressed in Canadian dollars unless otherwise noted.\n \n \n \n \n Selected Operational and Financial Highlights\n \n \n \n \n \n Announced receipt of advisory services and funding of up to\n \n $700,000\n \n from the\n \n National Research Council\n \n of Canada Industrial Research Assistance Program (\"NRC-IRAP\") to support a research and development project to further develop the Company's polymer-based proprietary drug delivery technology.\n \n \n Announced the start of patient screening for inclusion into its Phase 2 trial, which is evaluating EP-104IAR's efficacy and safety as a treatment for knee osteoarthritis (\"OA\"). The Company continues to expect to receive top-line results from the trial in late 2022.\n \n \n Received authorization of its Clinical Trial Application by the Danish Medicines Agency, which is required to initiate the Company's Phase 2 clinical trial for its lead candidate EP-104IAR as a potential treatment for pain from OA of the knee.\n \n \n Announced the publication of its Phase 1 EP-104IAR results in highly regarded, peer-reviewed journal\n \n Osteoarthritis and Cartilage Open\n \n .\n \n \n Received a Notice of Allowance from the Israel Patent Office with respect to its patent application\n \n Injectable Sustained Release Composition and Method of using the Same for Treating Inflammation in Joints and Pain Associated Therewith.\n \n \n \n \n \"By starting patient screening, we continued to execut...